dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Bataller Fernández, Marina |
dc.contributor.author | Sanchez Garcia, Almudena |
dc.contributor.author | Garcia Mayea, Yoelsis |
dc.contributor.author | Mir Perez, Cristina |
dc.contributor.author | Rodriguez Hernández, M. Isabel |
dc.contributor.author | Lleonart Pajarin, Matilde |
dc.date.accessioned | 2022-06-15T13:00:51Z |
dc.date.available | 2022-06-15T13:00:51Z |
dc.date.issued | 2021-12 |
dc.identifier.citation | Bataller M, Sánchez-García A, Garcia-Mayea Y, Mir C, Rodriguez I, LLeonart ME. The Role of Sphingolipids Metabolism in Cancer Drug Resistance. Front Oncol. 2021 Dec;11:807636. |
dc.identifier.issn | 2234-943X |
dc.identifier.uri | https://hdl.handle.net/11351/7692 |
dc.description | Ceramidasa àcida (AC); Glucosilceramida sintasa (GCS); Esfingolípids |
dc.description.sponsorship | We thank Teresa Moline and Rosa Somoza from the VHIR. This work was supported by grants from the Instituto de Salud Carlos III (ISCIII; PI20/00556 and CP03/00101 [ML]) and CIBERONC (ML). This work was also co-financed by the European Regional Fund (ERDF) and AECC (Spanish Association of Cancer Research) (Founding Ref. GC16173720CARR [ML]). YG-M, CM, and AS-G were supported by the VHIR, iP-FIS (ISCIII) and VHIR fellowships, respectively. |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Oncology;11 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Resistència als medicaments |
dc.subject | Càncer - Tractament |
dc.subject | Esfingolípids - Metabolisme |
dc.subject.mesh | Sphingolipids |
dc.subject.mesh | /metabolism |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | Drug Resistance |
dc.title | The Role of Sphingolipids Metabolism in Cancer Drug Resistance |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fonc.2021.807636 |
dc.subject.decs | esfingolípidos |
dc.subject.decs | /metabolismo |
dc.subject.decs | neoplasias |
dc.subject.decs | resistencia a medicamentos |
dc.relation.publishversion | https://doi.org/10.3389/fonc.2021.807636 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Bataller M, Sánchez-García A, Garcia-Mayea Y, Mir C] Grup de Recerca Biomèdica en Cèl•lules Mare de Càncer, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Rodriguez I] Servei de Gestió d'Infermeria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [LLeonart ME] Grup de Recerca Biomèdica en Cèl•lules Mare de Càncer, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Spanish Biomedical Research Network Centre in Oncology, CIBERONC, Madrid, Spain |
dc.identifier.pmid | 35004331 |
dc.identifier.wos | 000744980900001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00556 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |